DGAP-News: Rentschler Biopharma Expands Leadership Team with Senior-Level Hires

Rentschler Biopharma Expands Leadership Team with
Senior-Level Hires

• Dr. Sabine Sydow, former Head of industry association vfa bio, joins Rentschler Biopharma as Chief of Staff
• Falk Nuernberger appointed to newly created position of Corporate General Counsel

Laupheim, Germany, August 10, 2022 – Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, is expanding its Leadership Team with two experienced leaders in the areas of strategy and law. These newly created internal advisory functions will play an important role in the continued international expansion of Rentschler Biopharma's business.

Dr. Sabine Sydow joined Rentschler Biopharma on July 1, 2022 and is supporting the Executive Board as Chief of Staff. Through her many years as head of vfa bio (biotechnology interest group within the German Association of Research-Based Pharmaceutical Companies, vfa), she gained an in-depth understanding of the biopharmaceutical industry and has an excellent network in business, academia, and government. As Chief of Staff, Dr. Sabine Sydow serves as an advisor, connecting the Executive Board with all parts of the company. “I am very pleased to join Rentschler Biopharma and to help shape the future of this innovative and forward-looking company. In line with the company’s guiding principle, 'Many hands. Many minds. One team,' I am excited to help implement the Board’s initiatives and also share employees’ ideas with management,” said Dr. Sabine Sydow. In addition to her nearly 16 years at vfa bio, which she helped to grow and which she managed, she also brings corporate experience from Schering AG, where she held several positions, including as Director Business Management and Communication, Global Oncology until 2006. Dr. Sydow received her Ph.D. in biology from the Georg-August-University in Goettingen and worked as a scientist in the areas of neuroscience and molecular biology.

Falk Nuernberger joined Rentschler Biopharma as Corporate General Counsel on July 1, 2022. In this position, he will advise management in all legal matters. “It is exciting that, even after 150 years of company history, Rentschler Biopharma continues to transform itself through innovation and international growth. It is a great pleasure for me to be part of this highly professional and motivated team, and to serve as management’s legal advisor,” said Falk Nuernberger. Previously, he worked for several years as General Counsel Europe and as a member of the European management team of the pharmaceutical company Viatris, where he led the international team of the European legal department. Mr. Nuernberger also held various senior positions in the legal departments of MediGene, Sandoz and Actavis. Earlier in his career, he worked for law firms specializing in corporate and tax law. Mr. Nuernberger graduated in law from the University of Bayreuth and passed the bar exam in Munich. He holds a Master of Business Administration from Henley Business School.

“I am very pleased to welcome Sabine and Falk to Rentschler Biopharma. With their in-depth knowledge of our industry and their professionalism and sound judgment, we are gaining two very valuable senior team members,” commented Dr. Frank Mathias, CEO of Rentschler Biopharma. “I have a long-standing relationship with Sabine from her time at vfa bio, where we worked together to educate the public about the contributions of our industry in improving patient lives. I particularly appreciate her great openness to different points of view, as evidenced by her wide-ranging network of representatives from industry and government, as well as from scientific and patient organizations. With Falk, we have gained a highly competent lawyer with more than 20 years of practical experience in diverse areas of life sciences law. He also brings proven expertise in strategic risk management and in leading and developing strong teams. This positions him perfectly to help shape the continued successful development of Rentschler Biopharma. I am very much looking forward to working with Sabine and Falk. Their counsel will be instrumental in guiding and advancing our company’s strategic growth.”

About Rentschler Biopharma SE

Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. The company offers process development and manufacturing of biopharmaceuticals as well as related consulting activities, including project management and regulatory support. Rentschler Biopharma's high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. In order to offer best-in-class formulation development along the biopharmaceutical value chain, the company has entered into a strategic alliance with Leukocare AG. Rentschler Biopharma is a family-owned company with about 1,100 employees, headquartered in Laupheim, Germany, with a second site in Milford, MA, USA. In Stevenage, UK, Rentschler Biopharma has launched a company dedicated to cell and gene therapies, Rentschler ATMP Ltd.

For further information, please visit www.rentschler-biopharma.com. Follow Rentschler Biopharma on LinkedIn and Facebook.

Contact:
Rentschler Biopharma SE

Dr. Cora Kaiser

Senior Director Corporate Communication

Phone: +49-7392-701-874
[email protected]

Media inquiries:
MC Services AG    

Eva Bauer      

Phone: +49-89-210228-0   
[email protected]

U.S.

Laurie Doyle

Phone: +1-339-832-0752

For high-resolution images please contact [email protected].